266 related articles for article (PubMed ID: 28224463)
1. Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain.
Mezquita-Raya P; Ramírez de Arellano A; Kragh N; Vega-Hernandez G; Pöhlmann J; Valentine WJ; Hunt B
Diabetes Ther; 2017 Apr; 8(2):401-415. PubMed ID: 28224463
[TBL] [Abstract][Full Text] [Related]
2. Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.
Hunt B; Kragh N; McConnachie CC; Valentine WJ; Rossi MC; Montagnoli R
Clin Ther; 2017 Jul; 39(7):1347-1359. PubMed ID: 28625506
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting.
Hunt B; Vega-Hernandez G; Valentine WJ; Kragh N
Diabetes Obes Metab; 2017 Jun; 19(6):842-849. PubMed ID: 28124820
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom.
Hunt B; Ye Q; Valentine WJ; Ashley D
Diabetes Ther; 2017 Feb; 8(1):129-147. PubMed ID: 28058656
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence.
Raya PM; Blasco FJA; Hunt B; Martin V; Thorsted BL; Basse A; Price H
Diabetes Obes Metab; 2019 Jun; 21(6):1349-1356. PubMed ID: 30740861
[TBL] [Abstract][Full Text] [Related]
6. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.
Barnett AH; Arnoldini S; Hunt B; Subramanian G; Hoxer CS
Diabetes Obes Metab; 2018 Aug; 20(8):1921-1927. PubMed ID: 29652101
[TBL] [Abstract][Full Text] [Related]
7. Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin.
Mezquita Raya P; Pérez A; Ramírez de Arellano A; Briones T; Hunt B; Valentine WJ
Diabetes Ther; 2013 Dec; 4(2):417-30. PubMed ID: 24132613
[TBL] [Abstract][Full Text] [Related]
8. The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.
Franch-Nadal J; Malkin SJP; Hunt B; Martín V; Gallego Estébanez M; Vidal J
Adv Ther; 2022 Jul; 39(7):3180-3198. PubMed ID: 35553372
[TBL] [Abstract][Full Text] [Related]
9. Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia.
Malkin SJP; Russel-Szymczyk M; Liidemann G; Volke V; Hunt B
Diabetes Ther; 2019 Feb; 10(1):159-176. PubMed ID: 30535837
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United States.
Hunt B; McConnachie CC; Gamble C; Dang-Tan T
J Med Econ; 2017 Nov; 20(11):1117-1120. PubMed ID: 28651479
[TBL] [Abstract][Full Text] [Related]
11. Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.
Gæde P; Johansen P; Tikkanen CK; Pollock RF; Hunt B; Malkin SJP
Diabetes Ther; 2019 Aug; 10(4):1297-1317. PubMed ID: 31098942
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
Chuang LH; Verheggen BG; Charokopou M; Gibson D; Grandy S; Kartman B
J Med Econ; 2016 Dec; 19(12):1127-1134. PubMed ID: 27310712
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
Valentine WJ; Palmer AJ; Lammert M; Langer J; Brändle M
Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin.
Pérez A; Mezquita Raya P; Ramírez de Arellano A; Briones T; Hunt B; Valentine WJ
Diabetes Ther; 2015 Mar; 6(1):61-74. PubMed ID: 25742705
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting.
Martín V; Vidal J; Malkin SJP; Hallén N; Hunt B
Adv Ther; 2020 Oct; 37(10):4427-4445. PubMed ID: 32862365
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus.
Capel M; Ciudin A; Mareque M; Rodríguez-Rincón RM; Simón S; Oyagüez I
Pharmacoecon Open; 2020 Jun; 4(2):277-286. PubMed ID: 31338828
[TBL] [Abstract][Full Text] [Related]
17. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
Lee WC; Samyshkin Y; Langer J; Palmer JL
J Med Econ; 2012; 15 Suppl 2():28-37. PubMed ID: 22834986
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France.
Roussel R; Martinez L; Vandebrouck T; Douik H; Emiel P; Guery M; Hunt B; Valentine WJ
J Med Econ; 2016; 19(2):121-34. PubMed ID: 26413789
[TBL] [Abstract][Full Text] [Related]
19. Treating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixi.
Pöhlmann J; Russel-Szymczyk M; Holík P; Rychna K; Hunt B
Diabetes Ther; 2019 Apr; 10(2):493-508. PubMed ID: 30706364
[TBL] [Abstract][Full Text] [Related]
20. Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme.
Bain SC; Hansen BB; Malkin SJP; Nuhoho S; Valentine WJ; Chubb B; Hunt B; Capehorn M
Diabetes Ther; 2020 Jan; 11(1):259-277. PubMed ID: 31833042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]